Fig. 1From: Frontline treatment patterns and attrition rates by subsequent lines of therapy in patients with newly diagnosed multiple myelomaFrequently used frontline treatment regimens for patients with NDMM (a) who did not receive stem cell transplant (non-transplant) and (b) who received stem cell transplant (transplant). NDMM Newly diagnosed multiple myeloma, Vd Bortezomib/dexamethasone, Rd Lenalidomide/dexamethasone, VRd Bortezomib/lenalidomide/dexamethasone, V/alkylator Bortezomib/alkylating agent, V Bortezomib, R Lenalidomide, T Thalidomide. aOther regimens include other combinations of novel agents, such as Td and VR, as well as treatment with cyclophosphamide-containing regimensBack to article page